Pharma BD Deal Intelligence
Collapsed: the ~$160B Pfizer-Allergan merger died the moment Treasury's April 2016 anti-inversion rules hit, with Pfizer paying just $150M to walk away from what would have been the largest pharma deal ever.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Reports indicated Pfizer was prepared to walk despite a potential breakup fee, signaling that the Treasury's adverse tax law change had stripped the deal's…
Analysts argued Pfizer would now need to pursue alternative bolt-on M&A (Biogen, Regeneron, AbbVie cited) to compensate for losing access to Allergan's growth…
C&EN's year-end retrospective described the Pfizer-Allergan breakup as the defining pharma M&A event of 2016, reshaping U.S. tax-driven dealmaking for years…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Pfizer and Allergan terminated their previously announced ~$160B merger by mutual agreement following U.S. Treasury anti-inversion regulations issued April 4, 2016, which the companies determined qualified as an Adverse Tax Law Change. Pfizer paid Allergan $150M for expense reimbursement. Originally announced November 2015 with $363.63/share consideration; would have been the largest pharma deal in history.
$60.0B Combined Pfizer + Allergan 2015 sales (~$60B) · $150M Expense reimbursement paid to Allergan on termination
The proposed Pfizer-Allergan combination would have spanned a broad branded pharmaceutical portfolio rather than a single disease — covering medical aesthetics (Botox), eye care (Restasis), CNS (Namenda), GI (Linzess), and women's health. The strategic logic was tax inversion plus scale, not therapeutic-area depth in any one indication.
Had it closed, the $160B Pfizer-Allergan combination would have been the largest pharma deal in history, redomiciling Pfizer to Ireland and creating a roughly $60B revenue company spanning Pfizer's primary care/oncology engine (Lyrica, Ibrance, Prevnar) and Allergan's specialty franchises (Botox, Restasis, Linzess, Namenda XR). The deal collapsed April 6, 2016 after the U.S. Treasury issued anti-inversion rules on April 4, 2016 that retroactively excluded Allergan's three years of acquired assets — effectively shrinking Allergan below the 40% equity threshold required for inversion benefits and rendering the tax thesis moot. Pfizer paid Allergan $150M for expense reimbursement. The competitive set Pfizer would have absorbed remained intact: Botox in aesthetics versus Galderma/Merz Dysport, Restasis in dry eye versus Shire's Xiidra, Linzess versus Ironwood-partnered Trulance. Termination forced both companies to rebase: Pfizer pursued bolt-ons (Medivation, Anacor) while Allergan was eventually acquired by AbbVie in 2020.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Allergan plc (this deal) | 2016 | $160.0B | — |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2016 deals · Pfizer Inc. deals · Neurology deals